The natural history of multiple sclerosis

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 433-447

  Vukusic, Sandra ^a   Confavreux, Christian ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056681539     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. Fog T, Linneman F. The course of multiple sclerosis in 73 cases with computer designed curves. Acta Neurol Scand 1970; 46(suppl 47):1-175.
2. Percy AK, Nobrega FT, Okazaki H, Glattre E, Kurland LT. Multiple sclerosis in Rochester, Minn: A 60-year appraisal. Arch Neurol 1971; 25:105-111.
3. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis-Early prognostic features of the later course of the illness. J Chronic Dis 1977; 30:819-830.
4. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103:281-300.
5. Clark VA, Detels R, Visscher BR, Valdiviezo NL, Malmgren RM, Dudley JP. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982; 248:856-860.
6. Poser S, Poser W, Schlaf G, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986; 74:387-392.
7. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: Results from an epidemiological survey in north-east Scotland. J Neurol Neurosurg Psychiatry 1987; 50:523-531.
8. Minderhoud JM, Van der Hoeven JH, Prange AJA. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 1988; 78:10-15.
9. Riise T, Gronning M, Aarli JA, Nyland H, Larsen JP, Edland A. Prognostic factors for life expectancy in multiple sclerosis analised by Cox-models J Clin Epidemiol 1988; 41(10):1031-1036.
10. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographical based study. I. Clinical course and disability. Brain 1989; 112:133-146.
11. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospective followed-up population with multiple sclerosis: Implications for clinical trials. Arch Neurol 1989; 46(10):1107-1112.
12. Weishenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographical based study-II. Predictive value of the early clinical course. Brain 1989; 112:1419-1428.
13. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113:1597-1628.
14. Weinshenker BG, Rice GPA, Noseworthy JH, Cariere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographical based study-III. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114:1045-1056.
15. Weinshenker BG, Rice GPA, Noseworthy JH, Carniere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographical based study-IV. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114:1057-1067.
16. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: A regional study with some longitudinal data. J Neurol Neurosurg Psychiatry 1992; 55(5):341-346.
17. Riise T, Gronning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM, et al. Early prognostic factors for disability in multiple sclerosis: A European multicenter study. Acta Neurol Scand 1992; 85:212-218.
18. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 1993; 116:117-134.
19. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994; 241:597-604.
20. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, et al. Multivariate analysis of predictive factors of multiple sclerosis with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58:300-306.
21. Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study. Arch Neurol 1996; 53:353-358.
22. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. Primary progressive multiple sclerosis. Brain 1997; 120:1085-1096.
23. McDonnel GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 1998; 64:451-454.
24. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51(3):765-772.
25. Confavreux C, Grimaud J, Vukusic S, Moreau T. Peut-on prédire l’évolution de la sclérose en plaques? Rev Neurol 1998; 154(8-9):624-628.
26. Kremenchutzky M, Cottrel D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: A geographical based study-VII. Progressive-relapsing and relapsing-progressive multiple sclerosis: a reevaluation. Brain 1999; 122:1941-1949.
27. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168(2):96-106.
28. Ebers GC. Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, Mc-Donald I, Matthews B, Wekerle H, eds. McAlpine’s Multiple Sclerosis, 3rd ed. London: Churchill Livingstone, 1998.
29. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committe on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course: Results of an international survey. Neurology 1996; 46:907-911.
30. Yudkin PL, Ellison GW, Ghezzi A., et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051-1055.
31. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: A nationwide, long-term epidemiologic survey. Neurology 1994; 44(10): 1901-1907.
32. Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983; 40:533-536.
33. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in MS: Report by the panel on the evaluation of experimental trials of therapy in MS. Ann NY Acad Sci 1965; 122:552-568.
34. School GB, Song HS, Wray SH. Uhthoff’s symptom in optic neuritis: Relationship to magnetic resonance imaging and development of multiple sclerosis. Ann Neurol 1991; 30:180-184.
35. Douglass LH, Jorgensen CL. Pregnancy and multiple sclerosis. Am J Obstet Gynecol 1948; 55:332-336.
36. Tillman AJB. The effect of pregnancy on multiple sclerosis and its management. Res Publ Assoc Res Nerv Ment Dis 1950; 28:548-582.
37. Sweeney WJ. Pregnancy and multiple sclerosis. Am J Obstet Gynecol 1953; 66:124-130.
38. Birk K, Rudick R. Pregnancy and multiple sclerosis. Arch Neurol 1986; 43:719-726.
39. Hutchinson M. Pregnancy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 1043-1045.
40. Abramsky O. Pregnancy and multiple sclerosis. Ann Neurol 1994; 36 (suppl):S39-S41.
41. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, and the Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998; 339:285-291.
42. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, et al. A multicenter, randomised, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997; 48:312-314.